Alligator Bioscience raises 51 MSEK in new share issue

Alligator Bioscience, the protein optimization company has raised 51 MSEK in a new round of equity financing. New investors participating in the financing include the Norwegian investment company Home Capital AS, 1,7% of total shares, Swedish East Bay Holding AB and Malmsten Invest, at 1,4 and 1 % of total shares, respectively.

The capital will prepare the company for a planned IPO in about 2 years. Alligator Bioscience uses its proprietary FIND® technology to develop new and optimize existing therapeutic and diagnostic proteins. Since 2001, Alligator Bioscience has successfully collaborated with several companies in the pharmaceutical, diagnostic and biotech industry, improving customers' proteins and helping them to build more competitive pipelines.

The company has also created an internal pipeline of therapeutic drug candidates for major clinical indications, which are at varying stages of development. Alligator Bioscience operates from the Ideon Science Park in Lund, and has 23 employees. The company has around 150 shareholders.

Visit the Alligator Bioscience homepage.

Source: Press release, 29.05.2007